Holen Sie sich die Stockscreener-App
52.62
1.52%
0.79
Handel nachbörslich:
52.62
Schlusskurs vom Vortag:
$51.83
Offen:
$52
24-Stunden-Volumen:
754.33K
Relative Volume:
0.86
Marktkapitalisierung:
$5.51B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
64.96
EPS:
0.81
Netto-Cashflow:
$142.60M
1W Leistung:
-10.90%
1M Leistung:
+5.77%
6M Leistung:
+87.33%
1J Leistung:
+103.09%
1-Tages-Spanne:
$51.69
$52.99
1-Wochen-Bereich:
$51.51
$59.98
52-Wochen-Spanne:
$20.84
$61.66
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CORT | 52.62 | 5.51B | 628.56M | 141.82M | 142.60M | 0.81 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Cornercap Investment Counsel Inc. Has $426,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Royce & Associates LP Has $16.81 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Teva Defends Mifepristone Antitrust Case Against Corcept - Law360
Intellectus Partners LLC Purchases Shares of 54,859 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $131,736 in stock By Investing.com - Investing.com Australia
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Principal Financial Group Inc. - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $131,736 in stock - Investing.com
Cushing's Syndrome Market to Show a Rise During the Study Period | - openPR
Cushing's Syndrome Market Will Drive an Exponential CAGR - openPR
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
24,800 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Versor Investments LP - MarketBeat
Wealth Enhancement Advisory Services LLC Takes $238,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Lisanti Capital Growth LLC Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
CWA Asset Management Group LLC Acquires Shares of 20,800 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 8.9%Time to Buy? - MarketBeat
US Bancorp DE Purchases 12,177 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
M&G Plc Buys New Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - MSN
New York State Teachers Retirement System Sells 17,222 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics' chief development officer sells $489,700 in stock - Investing.com
Corcept Therapeutics' chief development officer sells $489,700 in stock By Investing.com - Investing.com UK
Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance
Corcept (CORT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews
Roman Butler Fullerton & Co. Has $261,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Sets New 1-Year HighWhat's Next? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia
Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Finance
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance
What is HC Wainwright’s Forecast for CORT FY2024 Earnings? - Defense World
HC Wainwright Has Bullish Forecast for CORT FY2024 Earnings - MarketBeat
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity - GuruFocus.com
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat
FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey
Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings: EPS of $0.41 B - GuruFocus.com
Corcept Therapeutics' (CORT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates - MSN
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):